Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma.

被引：0

作者：

Willson, Jenny

Bruno, Amanda

Opalinska, Joanna

Nelson, Jeanenne Joy

Lunacsek, Orsolya

Stafkey-Mailey, Dana

Willey, Joanne P.

机构：

[1] GSK, London, England

[2] GlaxoSmithKline, Collegeville, PA USA

[3] GlaxoSmithKline, Res Triangle Pk, NC USA

[4] Xcenda, Palm Harbor, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.e20038

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20038

引用

页数：2

共 50 条

[41] Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma
Mark, Tomer
Falkenstein, Angelica
Kish, Jonathan
[J]. FUTURE ONCOLOGY, 2022, 18 (05) : 553 - 564
[42] KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.
Jagannath, Sundar
Lin, Yi
Goldschmidt, Hartmut
Reece, Donna Ellen
Nooka, Ajay K.
Otero, Paula Rodriguez
Matsue, Kosei
Shah, Nina
Anderson, Larry D., Jr.
Wilson, Kimberly
Swern, Arlene S.
Zafar, Faiza
Agarwal, Amit Balkrishna
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[43] Real-World Treatment Patterns and Patient Outcomes in Relapsed/Refractory Hodgkin Lymphoma in the US
Kristo, Fjoralba
Lingohr-Smith, Melissa
Lin, Jay
Ashaye, Ajibade
[J]. BLOOD, 2023, 142
[44] Real-World Treatment Patterns in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Chart Review in the United Kingdom
Lin, Huamao Mark
Davis, Keith
Kaye, James
Luptakova, Katarina
Lu, Gao
Nagar, Saurabh
Seal, Brian
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E133 - E134
[45] Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies
Taku Kikuchi
Nobuhiro Tsukada
Kodai Kunisada
Moe Nomura-Yogo
Yuki Oda
Kota Sato
Tomomi Takei
Mizuki Ogura
Yu Abe
Kenshi Suzuki
Tadao Ishida
[J]. Annals of Hematology, 2023, 102 : 3489 - 3497
[46] Real-world clinical outcomes in patients with relapsed and refractory multiple myeloma receiving VTD-PACE treatment in the era of monoclonal antibodies
Kikuchi, Taku
Tsukada, Nobuhiro
Kunisada, Kodai
Nomura-Yogo, Moe
Oda, Yuki
Sato, Kota
Takei, Tomomi
Ogura, Mizuki
Abe, Yu
Suzuki, Kenshi
Ishida, Tadao
[J]. ANNALS OF HEMATOLOGY, 2023, 102 (12) : 3489 - 3497
[47] A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study
Rios-Tamayo, Rafael
Soler, Juan Alfons
Garcia-Sanchez, Ricarda
Persona, Ernesto Perez
Arnao, Mario
Garcia-Guinon, Antoni
Domingo, Abel
Gonzalez-Pardo, Miriam
de la Rubia, Javier
Mateos, Maria Victoria
[J]. HEMATOLOGY, 2023, 28 (01)
[48] DURATION OF THERAPY IN US PATIENTS TREATED FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN THE REAL-WORLD
Romanus, D.
Raju, A.
Yong, C.
Seal, B.
Farrelly, E.
Noga, S.
Jhaveri, M.
Labotka, R.
Blazer, M.
Parameswaran, H.
[J]. HAEMATOLOGICA, 2016, 101 : 538 - 539
[49] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
Hultcrantz, Malin
Derkach, Andriy
Hassoun, Hani
Korde, Neha
Maclachlan, Kylee H.
Mailankody, Sham
Patel, Dhwani
Shah, Urvi A.
Tan, Carlyn
Akhlaghi, Theresia
Hamadeh, Issam S.
Chung, David J.
Lahoud, Oscar B.
Landau, Heather
Scordo, Michael
Shah, Gunjan L.
Giralt, Sergio A.
Lesokhin, Alexander M.
Usmani, Saad
[J]. BLOOD, 2022, 140 : 7246 - 7248
[50] Real-world utilization patterns of PI and IMiD combination therapy as treatment for relapse multiple myeloma.
Maiese, Eric M.
Slaton, Terra
Macomson, Brian
Kozma, Chris M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →